

# 1 Translation of core terms of chemical risk assessment into the 2 language of systematic review: research protocol

3 Camilla Svendsen<sup>1,2†</sup>, Gro H. Mathisen<sup>1</sup>, Gunn E. Vist<sup>1,3</sup>, Trine Husøy<sup>1,4</sup>, Heather M. Ames<sup>1,3</sup>,  
4 Anna Beronius<sup>5</sup>, Emma Di Consiglio<sup>6</sup>, Ingrid Druwe<sup>7</sup>, Thomas Hartung<sup>8,9</sup>, Sebastian  
5 Hoffmann<sup>10,11</sup>, Carlijn R. Hooijmans<sup>12</sup>, Kyriaki Machera<sup>13</sup>, Joshua F. Robinson<sup>14</sup>, Erwin  
6 Roggen<sup>15</sup>, Andrew A. Rooney<sup>16</sup>, Nicolas Roth<sup>17,18</sup>, Eliana Spilioti<sup>13</sup>, Anastasia Spyropoulou<sup>13</sup>,  
7 Olga Tcheremenskaia<sup>6</sup>, Emanuela Testai<sup>6</sup>, Mathieu Vinken<sup>19</sup>, Paul Whaley<sup>1,20†</sup>

8 <sup>1</sup>Norwegian Scientific Committee for Food and Environment, Norwegian Institute of Public  
9 Health, Oslo, Norway

10 <sup>2</sup>Department of Chemical Toxicology, Norwegian Institute of Public Health, Oslo, Norway

11 <sup>3</sup>Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway

12 <sup>4</sup>Department of Food Safety, Norwegian Institute of Public Health, Oslo, Norway

13 <sup>5</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

14 <sup>6</sup>Environment & Health Department, Italian National Institute of Health (ISS), Rome, Italy

15 <sup>7</sup>United States Environmental Protection Agency, Office of Research and Development,  
16 Center for Public Health and Environmental Assessments, Research Triangle Park, NC,  
17 USA.

18 <sup>8</sup>Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Bloomberg  
19 School of Public Health, Baltimore, MD, USA

20 <sup>9</sup>CAAT Europe, University of Konstanz, Konstanz, Germany

21 <sup>10</sup>Evidence-based toxicology collaboration (EBTC), Johns Hopkins University, Bloomberg  
22 School of Public Health, Baltimore, MD, USA

23 <sup>11</sup>seh consulting + services, Paderborn, Germany

24 <sup>12</sup>Department of Anesthesiology, Pain and Palliative Care, Radboud University Medical  
25 Centre, Nijmegen, Netherlands

26 <sup>13</sup>Laboratory of Toxicological Control of Pesticides, Scientific Directorate of Pesticides'  
27 Control and Phytopharmacy, Benaki Phytopathological Institute, Kifissia, Greece

28 <sup>14</sup>Department of Obstetrics, Gynecology & Reproductive Sciences, University of California,  
29 San Francisco (UCSF), USA

30 <sup>15</sup>3Rs Management and Consulting ApS, Lyngby, Denmark

31 <sup>16</sup>Division of Translational Toxicology, National Institute of Environmental Health Sciences,  
32 Research Triangle Park, NC, USA

33 <sup>17</sup>Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

34 <sup>18</sup>Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Basel,  
35 Switzerland

36 <sup>19</sup>Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel;  
37 Belgium

38 <sup>20</sup>Lancaster Environment Centre, Lancaster University, Lancaster, UK

39 †Correspondence should be addressed to Camilla Svendsen; E-mail:  
40 camilla.svendsen@fhi.no and Paul Whaley; E-mail: paul@whaleyresearch.uk.

## 41 Disclaimer

42 The author Ingrid Druwe is employed at the U.S. Environmental Protection Agency. The  
43 views expressed in this manuscript are those of the authors and do not necessarily  
44 represent the views or policies of the U.S. Environmental Protection Agency.

45 The author Andrew Rooney is employed at the U.S. National Institute of Environmental  
46 Health Sciences. The views expressed in this manuscript are those of the authors and do  
47 not necessarily represent the views or policies of the U.S. National Institute of Environmental  
48 Health Sciences.

## 49 Abstract

50 The focus on implementation of systematic review (SR) principles in chemical risk  
51 assessments (CRAs) is growing as it has the potential to advance the rigour and  
52 transparency of the CRAs. However, the SR and CRA communities use their own specific  
53 terminologies. Understanding the meaning of core SR and CRA terms and where they  
54 overlap is critical for application of SR methods and principles in CRAs. Moreover, it will  
55 increase the possibility for cross-sectorial collaboration, avoid misunderstandings, and  
56 improve communication among risk assessors, researchers, and policy makers.

57 We present a process for the translation of core CRA terms into the SR language. Core  
58 terms for study appraisal, evidence synthesis and integration used in the SR and CRA  
59 communities will be included. The outcome will be an overview of how core SR terms map

60 onto core CRA terms and a description of the relationship and conceptual overlap between  
61 the terms.

62 The cross-mapping is divided in four phases, where in the first phase the core SR and CRA  
63 terms will be identified. In the second phase, existing CRA definitions will be mapped.  
64 Authoritative definitions for core SR terms will be derived in the third phase. In the fourth  
65 phase descriptions of the relationship and conceptual overlap between the terms will be  
66 derived. The third and fourth phase will include weekly one-hour online meetings for SR and  
67 CRA experts.

## 68 Key words

69 Conceptual overlap, cross-mapping, definitions, interoperability, terminology.

## 70 1. Introduction

71 Chemical risk assessments (CRAs) should be evidence-based, which means that they are  
72 grounded in a comprehensive and rigorous, transparent and objective analysis of all  
73 evidence relating to the assessment task. Applying systematic review (SR) principles in  
74 CRAs has become an established methodology for achieving this goal, from its first practical  
75 introduction in 2013-14 (NTP OHAT, 2015; Woodruff and Sutton, 2014), its popularisation in  
76 the following few years (Hoffmann et al., 2017; Whaley et al., 2016), and its wider uptake by  
77 national and international risk assessment agencies including US EPA (EPA, 2022; EPA,  
78 2023), EFSA (EFSA, 2010; EFSA et al., 2017a), and WHO (WHO, 2021).

79 Because SR and CRA methodologies were developed independently of each other, the SR  
80 and CRA communities use their own specific terminologies and language. Numerous SRs  
81 performed as part of CRAs have shown that these terminologies often are analogous to  
82 each other or overlapping, but rarely the same or directly translatable. It can therefore be  
83 difficult to understand which SR method (or to what level/extent) is applied in the CRAs (i.e.,  
84 whether a given framework or application is sufficiently rigorous to be described as  
85 “systematic”) and may be impeding the understanding and therefore potentially slowing the  
86 uptake of SR methods in the CRA community.

87 In this project, we will analyse conceptual overlap and differences between the core CRA  
88 terms of SR and CRA. This way, we aim to increase the interoperability of SR and CRA  
89 terminologies by improving the understanding of the meaning of and the relationships  
90 between the core terms of the respective domains.


## 91 1.1 Project governance

92 This project is a part of the “[Next generation risk assessment in practice](#)” project (VKM,  
93 2023) which is included in the European Partnership for the Assessment of Risks from  
94 Chemicals ([PARC](#); Project 101057014)”. The participants in this project include the  
95 members of the research team and the members of the scientific advisory group (SAG). A  
96 project group (PG) has been established with the responsibility for drafting the protocol and  
97 performing the study.

## 98 2 Methods

### 99 2.1 Study design

100 A cross-mapping of core SR and CRA terms will be performed to explore the relationship  
101 between the terms, to identify conceptual overlaps, and to identify how SR terms map onto  
102 CRA terms. By “core” we mean terms denoting key concepts in the study appraisal,  
103 evidence synthesis, and evidence integration steps of systematic reviews. The project is  
104 divided into four phases as shown in Figure 1.



105

106 **Figure 1.** Overview of the four phases and the timeline for the translation of core terms of  
107 systematic review into the language of chemical risk assessment. Abbreviations: CRA,  
108 chemical risk assessment; SR, systematic review.

109 The timeline for the project and estimated duration for each phase are shown in Figure 1.  
110 Phases 3 and 4 will include weekly one-hour online meetings for the discussion and

111 derivation of authoritative SR definitions and the descriptions of SR and CRA term  
112 relationships, and the anticipated duration of these phases is 3 to 5 months each.

## 113 2.2 Phase 1: Cataloguing core terms in SR and CRA terminologies

114 The objective is to catalogue core SR and CRA terms that are used for study appraisal,  
115 evidence synthesis and integration.

### 116 **Creating longlists of SR and CRA terms**

117 We will create a list of 400 SR terms and a list of 400 CRA terms as potential candidates for  
118 inclusion in this terminology cross-mapping, assuming that the core terms will be included in  
119 such extensive lists. The lists will be machine-generated using the Term Frequency - Inverse  
120 Document Frequency (TF-IDF) method. TF-IDF compares the relative importance of a term  
121 between two topic domains (in this case, SR or CRA compared with everyday general  
122 communication) by assuming that terms that are more important in the first domain will occur  
123 relatively infrequently in the second domain (Nettleton, 2014). For example, the term “bias” is  
124 a central term in SRs and can therefore be expected to occur with higher relative frequency  
125 in a corpus of SR documents than it will in a general language corpus. The terms that occur  
126 least frequently in the general corpus have a higher probability of being core terms in the  
127 domain of interest.

128 The TF-IDF method is an efficient way of generating a longlist of key terms as it does not  
129 require extensive interviewing of domain experts or the creation of a comprehensive corpus  
130 of the domain of interest. The only requirement is that the target domain terms occur at least  
131 once in the domain corpus, and the comparator corpus is representative of a different  
132 community of language users. In our case, the comparator corpus will be the English Web  
133 corpus enTenTen21 (Sketch Engine, 2023). enTenTen21 is an English language corpus  
134 made up of texts collected from the Internet. The target domain corpora will be (1) a  
135 selection of SR manuscripts, tools, and current guidelines from governmental and  
136 international agencies as well as SR professional organisations (Table 1), and (2) a selection  
137 of CRA manuscripts and current guidelines from governmental and international agencies as  
138 well as CRA professional organisations (Table 2). To maximise differences between the two  
139 long-lists, the systematic review documents should not be from the CRA or adjacent  
140 domains, and the CRA documents should not apply SR specific terms. In addition, the  
141 documents should include the concepts study appraisal, evidence integration and synthesis.

142 The longlists will be available as supplementary materials.

143 **Table 1.** The systematic review document collection.

<b>Document</b>	<b>Reference</b>
Cochrane Handbook for Systematic Reviews of Interventions version 6.3	Higgins et al. (2022)
Finding What Works in Health Care: Standards for Systematic Reviews	Institute of Medicine Committee on Standards for Systematic Reviews of Comparative Effectiveness (2011)
JBIC Manual for Evidence Synthesis	Aromataris et al. (2020)
Methodological Expectations of Cochrane Interventions Reviews (MECIR)	Higgins et al. (2023)
Handbook for Conducting a Literature Based Health Assessment Using OHAT Approach for Systematic Review and Evidence Integration	NTP OHAT (2019)
<i>Systematic reviews (n=5)</i>	<i>To be selected by the project group</i>

144

145 **Table 2.** The chemical risk assessment document collection.

<b>Document</b>	<b>Reference</b>
Framework for the use of systematic review in chemical risk assessment	WHO (2021)
Guidance on the assessment of the biological relevance of data in scientific assessments	EFSA et al. (2017b)
Guidance on information requirements and chemical safety assessment. Part B: Hazard assessment.	ECHA (2011)
Guidance on the use of the weight of evidence approach in scientific assessments	EFSA et al. (2017a)
Guiding Principles and Key Elements for Establishing a Weight of Evidence for Chemical Assessment	OECD (2019)

ORD Staff Handbook for Developing IRIS Assessments	EPA (2022)
Weight of Evidence: General Principles and Current Applications at Health Canada	Tao et al. (2018)
Risk Assessment in the Federal Government: Managing the Process	National Research Council Committee on the Institutional Means for Assessment of Risks to Public (1983)
Science and Decisions: Advancing Risk Assessment	National Research Council (2009)
<i>Chemical risk assessments (n=5)</i>	<i>To be selected by the project group</i>

146

147 **Creating shortlists and final shortlists of essential SR and CRA terms**

148 The essential SR and CRA terms will be selected from the extended lists of 400 terms by an  
 149 expert group consisting of PG and SAG members.

150 A minimum of four expert group members will individually screen each extended list in Excel,  
 151 with the terms presented in the TF-IDF rank order. CRA experts screen the longlist with CRA  
 152 terms and SR experts screen the longlist of SR terms. The expert group members will i)  
 153 highlight all terms perceived as relevant for study appraisal, evidence synthesis and  
 154 integration, and ii) add additional terms they believe should be included but are not on the  
 155 extended list. There will be no upper or lower limit on the number of terms that can be  
 156 highlighted as relevant. The possibility for the experts to include additional terms is  
 157 considered to take care of a possible problem that may be introduced if core terms are  
 158 abbreviated in the documents. An overview of all terms perceived as relevant will be created  
 159 and the experts will then be requested to i) categorise the terms according to importance  
 160 using the categories: “important”, “neither important or unimportant” and “unimportant”, and  
 161 ii) to indicate for each term for which of the three steps study appraisal, evidence integration  
 162 and synthesis the term is applied. The categorisation according to importance will be based  
 163 on the judgement of each individual expert.

164 In the next step, shortlists of SR and CRA terms categorised as “important” by one or more  
165 members of the expert group with information on the number of experts that categorised the  
166 term as “important”, will be created by the PG.

167 The shortlists will be presented and discussed in PG and SAG meetings to identify i) terms  
168 on the shortlist that are not related to study appraisal, evidence synthesis and integration  
169 process, and ii) additional terms that should be included. The final shortlists will be prepared  
170 by the PG and be available as supplementary materials.

### 171 **Cataloguing core SR and CRA terms**

172 To be included as a core term in the process of study appraisal, evidence synthesis and/or  
173 integration, the term must be i) perceived to be relevant AND ii) categorised as “important”  
174 by  $\geq 50\%$  of the expert group participating in the creation of the short lists.

175 PG will prepare the overview of SR and CRA terms fulfilling the core term criteria.

### 176 **2.3 Phase 2: Preparing a list of existing definitions of CRA terms**

177 The objective of this phase is to prepare a list of a representative range of definitions of the  
178 core CRA terms. Note that whereas we will derive definitions of the core SR terms in phase  
179 3, we will not reconcile varying definitions of the core CRA terms.

180 The definitions for the CRA terms will be collected from glossaries, guidance’s and/or  
181 assessments from the [European Chemicals Agency](#) (ECHA), the [European Food Safety](#)  
182 [Authority](#) (EFSA), the [National Toxicology Program](#) (NTP), the [Organisation for Economic](#)  
183 [Co-operation and Development](#) (OECD), and the [U.S. Environmental Protection Agency](#)  
184 (EPA). The definitions of the core CRA terms will be extracted by one PG member and  
185 checked by another PG member. The table will be made available as supplementary  
186 materials.

### 187 **2.4 Phase 3 Deriving definitions of core SR terms**

188 The objective of Phase 3 is to provide definitions of the core SR terms that are as accurate  
189 and unambiguous as possible. This will be done via a consensus process involving an SR  
190 expert group with PG and SAG members and additional experts self-identifying as having  
191 relevant SR expertise (see Section 2.6). The authoritative definitions will be derived  
192 according to a modified version of the SEVCO protocol for developing an ontology (Alper et  
193 al., 2021a; Alper et al., 2021b). The main steps for defining terms are shown in Table 3. A  
194 more detailed overview is included in the Supplementary materials (Table S-1).



195 **Table 3.** The process for defining a core SR term. PG, project group; SAG, scientific  
 196 advisory group; SEVCO, Scientific Evidence Code System; SR, systematic review.

Step	What
1. Definitions of core SR terms available in SEVCO are identified.	Relevant SEVCO definitions will be collected. These definitions will be the draft definitions used as the basis for discussions in step 4.
2. Commonly used definitions of the core SR terms are identified.  <i>This step is only performed for terms without a SEVCO definition.</i>	Definitions will be collected from the documents in Table 1. If definitions are not available in these documents, glossaries from the institutions preparing the manuals/handbooks will be used. Based on the collected definitions, a draft term definition will be suggested by the PG.
3. Assembling of an expert group with PG members, SAG members, and additional experts, all self-identifying as having relevant SR expertise.	
4. Identification of agreement on discussed definitions.	The expert group discusses the draft definitions, to develop a refined draft that can be put to vote for approval.  For approval of definitions, the expert group members vote in an asynchronous, blinded, online ballot “agree” or “not agree” on each discussed statement.  A definition is approved if at least 5 experts vote, and unanimously vote “yes”. “No” votes have to be accompanied by comments suggesting changes that could lead to agreement.  If a definition is approved, stop here.

	If a definition is not approved, proceed to step 5.
<p>5. Suggestion of changes to the descriptions where no agreement was reached.</p>	<p>The result of the vote and any accompanying comments are discussed in the expert group and the definition will be redrafted.</p> <p>The definition is put back out to vote. The criteria for agreement for definitions for terms that are discussed for the second time are: i) At least 5 members voted AND ii) at least 80% votes were for “agree”.</p> <p>If an agreement is reached, stop here.</p> <p>If no agreement is reached, proceed to step 4.</p> <p>Steps 4 and 5 are repeated a maximum of two times. If agreement is not reached, a definition of the term will not be derived, and the term will not be included in the next phase.</p>


197

198 We will work down the list of terms ranked in terms of importance (most categorisations as  
 199 “important” at the top). If we cannot complete the full list in the planned time (5 months) we  
 200 will stop, prioritising timely completion over comprehensiveness.

201 Synonymous SR terms will be identified by the expert group during this phase. For  
 202 synonymous SR terms, only one of the terms will be included in the cross-mapping in phase  
 203 4. However, the synonyms will be mapped onto the preferred term in phase 4.

204 **2.5 Phase 4: Identifying conceptual overlap between CRA and SR terms**

205 The objective is to identify areas of conceptual overlap and difference between CRA terms  
 206 and SR terms (as illustrated in Figure 2). The cross-mapping will be done via a consensus  
 207 process involving an expert group with PG and SAG members and additional experts (see  
 208 section 2.6) self-identifying as having relevant CRA and/or SR expertise. The main steps in  
 209 the cross-mapping are shown in Table 4. A more detailed overview of the steps is included  
 210 in the Supplementary materials (Table S-2).



211

212 **Figure 2.** Visual representation of the mapping of core concepts used in systematic review  
 213 (SR) onto core concepts used in chemical risk assessment (CRA). Circles represent the  
 214 conceptual space denoted by a term. Variants of SR term definitions are identified and  
 215 normalised into an authoritative definition. Variants of CRA term definitions and how they  
 216 relate to each other are described. Relations between SR concepts and CRA concepts are  
 217 then mapped onto each other, with potential for multiple relationships between individual SR  
 218 and CRA concepts.

219 The cross-mapping will be performed in decreasing rank order of the importance of CRA  
 220 terms, as determined by the number of times a term is classified as “important” by the expert  
 221 group.

222 **Table 4.** The four main steps in the cross-mapping process.

Step	What
1. Identification of relationships between core CRA terms and core SR terms.	PG will draft statements of how CRA and SR terms are related.

<p>2. Assembling an expert group with PG members, SAG members, and additional experts, all self-identifying as having relevant SR and/or CRA expertise.</p>	<p>The draft statements are discussed in the expert group and revised according to the discussion.</p>
<p>3. Identification of agreement on discussed descriptions (approval of the draft statements from step 2).</p>	<p>The experts vote (online) “agree” or “not agree” on approval of the draft statement from step 2.</p> <p>The criteria for agreement are: i) at least 5 members voted AND ii) all votes were for “agree”.</p> <p>If an agreement is reached, stop here.</p> <p>If no agreement is reached, proceed to step 4.</p>
<p>4. Suggestion of changes to the descriptions where no agreement was reached.</p>	<p>The result of the vote is discussed in the expert group and redrafted when needed. Participants will vote (online) “agree” or “not agree” on each discussed statement. The criteria for agreement for definitions for terms that are discussed for the second time are: i) at least 5 members voted AND ii) at least 80% of the votes were for “agree”.</p> <p>If an agreement is reached, stop here.</p> <p>If no agreement is reached, proceed to step 3.</p> <p>Steps 3 and 4 are repeated a maximum of two times. If agreement is not reached, no statement of the relationship between the CRA and the SR terms will be created.</p>

## 224 2.6 The expert groups participating in phases 3 and 4

225 The experts participating in the online meetings will be PG and SAG members and additional  
226 experts self-identifying as having relevant SR expertise (phase 3 expert group) and SR or  
227 CRA expertise (phase 4 expert group).

228 Recruitment of additional experts will be done by via PG and SAG networks. Anyone self-  
229 identifying as having the relevant expertise can sign up at any time. Expert group  
230 participants will be sent project updates, in particular notifications of when terms are open for  
231 vote, by email. Votes will be cast by email to the PG member tasked with facilitating the  
232 discussion and voting process. The facilitator will anonymise the votes to the rest of the PG  
233 and expert group.

234 Following the additional experts first participation, they will be asked to fill out a short  
235 questionnaire with questions about their affiliation, country of residence, gender, and number  
236 of years of experience with SRs (phase 3) or SRs and CRAs (phase 4).

237 Everyone on the mailing list will receive meeting documents in front of the meetings.  
238 Everyone that participated in a meeting will be asked to participate in the voting after the  
239 meeting. The votes will not be anonymous for the PG but will be anonymised in the  
240 manuscript.

241 Expert Group members are eligible to be co-authors if they i) vote and/or comment on at  
242 least ten terms or cross-mappings in total, and ii) reviews the manuscript. Expert group  
243 members not eligible to be co-authors will be listed in the acknowledgements. No financial  
244 compensation or other incentives are offered for the participation as additional expert.

## 245 3 Anticipated results

246 In this section we describe how the result of the study will be presented in the results section  
247 of the finalised manuscript. All other results will be made available as supplementary  
248 materials.

### 249 3.1 Core SR and CRA terms

250 A list of core terms in the SR and CRA terminologies, and the categorisation of each term  
251 according to importance, will be presented. A table illustrating a proposed way to present the  
252 results is included in the Supplementary materials (Table S-3).

## 253 3.2 SR and CRA term definitions

254 The authoritative definitions of SR core terms and their synonyms will be presented. In  
255 addition, the catalogue of CRA terms will be presented. Tables illustrating the presentation of  
256 the catalogues definitions of CRA terms and the collected and the derived authoritative  
257 definitions for the SR Terms are included in the Supplementary materials. Tables illustrating  
258 the presentation of the catalogued definitions of the core CRA terms, the authoritative  
259 definitions of SR terms and an overview of the synonymous SR terms are included in the  
260 Supplementary materials (Tables S-4 and S-5). The presentation of participant  
261 characteristics for the expert group participating in phase 3 is illustrated in the  
262 Supplementary materials (Table S-6).

## 263 3.4 Conceptual overlap between core SR and core CRA terms

264 Descriptions of the relationship between CRA terms and SR terms will be presented. Tables  
265 illustrating how this information will be presented are included in the Supplementary  
266 materials. The proposed presentation of the cross-mapping of CRA terms on the SR terms is  
267 shown in the Supplementary materials (Table S-7). The proposed presentation of the SR  
268 terms and the related CRA terms and the conceptual overlap is shown in the Supplementary  
269 materials (Table S-8). The proposed presentation of participant characteristics for the expert  
270 group participating in phase 4 is shown in the Supplementary materials (Table S-9).

## 271 4 Limitations

272 The methods described in this protocol are considered to provide a grounded process  
273 towards a common understanding for the meaning of these terms without being too time-  
274 consuming. A consequence may be that not all terms perceived as essential in all SR and  
275 CRA communities will be included. Not all versions of definitions of the CRA terms will be  
276 identified. If it turns out that additional terms need clarification, these can be included in a  
277 follow-up project.

278 While we attempt to involve a broad and diverse group of experts from several institutions in  
279 this project, it is possible that we will not be able to recruit participants from all relevant  
280 institutions within the SR and CRA communities. However, being able to distribute  
281 information through the networks of both the PG and the SAG, we expect to recruit  
282 participants from several relevant institutions.

## 283 Dissemination

284 The outcome of this project will be published in a scientific journal.

## 285 Abbreviations

286 CRA: chemical risk assessment

287 PG: project group

288 SAG: scientific advisory group

289 SEVCO: Scientific Evidence Code System

290 SR: systematic review

## 291 Definition

292 **Core terms** are in this project defined as terms denoting key concepts in the study  
293 appraisal, evidence synthesis, and evidence integration steps of systematic reviews.

## 294 Funding

295 Camilla Svendsen, Gro H. Mathisen, Gunn E. Vist, Trine Husøy, Heather M.R. Ames, Emma  
296 Di Consiglio, Kyriaki Machera, Eliana Spilioti, Anastasia Spyropoulou, Olga  
297 Tcheremenskaia, Emanuela Testai, and Paul Whaley were supported by HORIZON-HLTH-  
298 2021-ENVHLTH-03, Grant [101057014]; Nicolas Roth was supported by The Swiss State  
299 Secretariat for Education, Research and Innovation (SERI) under contract no. 22.00230.

## 300 Ethical considerations

301 Application for ethical approval will be submitted to the Norwegian Institute of Public Health.

## 302 Declaration of interests

303 Completed declaration of interest forms for each author are available as supplementary  
304 materials. The authors declare no potential conflicts of interest with respect to the research,  
305 authorship, and/or publication of this protocol.

## 306 Authors contribution

307 **Conceptualization:** Camilla Svendsen, Gro H. Mathisen, Gunn E. Vist, Trine Husøy, and  
308 Paul Whaley.

309 **Funding acquisition:** Camilla Svendsen and Gro H. Mathisen.

310 **Methodology:** Camilla Svendsen, Gro H. Mathisen, and Paul Whaley.

311 **Project administration:** Camilla Svendsen and Gro H. Mathisen.  
312 **Supervision:** Paul Whaley.  
313 **Visualization:** Camilla Svendsen, Gro H. Mathisen, and Paul Whaley.  
314 **Writing - original draft:** Camilla Svendsen, Gro H. Mathisen, Gunn E. Vist, and Paul  
315 Whaley.  
316 **Writing - review & editing:** Camilla Svendsen, Gro H. Mathisen, Gunn E. Vist, Trine Husøy,  
317 Heather M. Ames, Anna Beronius, Emma Di Consiglio, Ingrid Druwe, Thomas Hartung,  
318 Sebastian Hoffmann, Carlijn R. Hooijmans, Kyriaki Machera, Joshua F. Robinson, Erwin  
319 Roggen, Andrew A. Rooney, Nicolas Roth, Eliana Spilioti, Anastasia Spyropoulou, Olga  
320 Tcheremenskaia, Emanuela Testai, Mathieu Vinken, and Paul Whaley.

## 321 References

322 Alper B.S., Dehnbostel J., Afzal M., Subbian V., Soares A., Kunnamo I., Shahin K., McClure  
323 R.C. (2021a) Making science computable: Developing code systems for statistics,  
324 study design, and risk of bias. *Journal of Biomedical Informatics* 115:103685. DOI:  
325 10.1016/j.jbi.2021.103685.

326 Alper B.S., Dehnbostel J., Lehmann H., Whaley P., Wilkins K.J., Tufte J., Yurk R.A., Ojha N.,  
327 Afzal M. (2021b) For the COVID-19 Knowledge Accelerator (COKA) Initiative.  
328 Scientific Evidence Code System Development Protocol. Created November 16,  
329 2021. Last revised December 8, 2021. Available at:  
330 [https://docs.google.com/document/d/1pzGLdyVCKcu3s2gfSfPpXDQLIQsFnLZR14ld](https://docs.google.com/document/d/1pzGLdyVCKcu3s2gfSfPpXDQLIQsFnLZR14ldw0nD1g0)  
331 [w0nD1g0](https://docs.google.com/document/d/1pzGLdyVCKcu3s2gfSfPpXDQLIQsFnLZR14ldw0nD1g0).

332 Aromataris E., Munn Z., (Editors). (2020) *JBI Manual for Evidence Synthesis*. JBI, 2020.  
333 Available from <https://synthesismanual.jbi.global>. [https://doi.org/10.46658/JBIMES-](https://doi.org/10.46658/JBIMES-20-01)  
334 [20-01](https://jbi-global-wiki.refined.site/space/MANUAL/4685874/Downloadable+PDF+-+current+version?attachment=/rest/api/content/4685874/child/attachment/att4691824/download&type=application/pdf&filename=JBIMES_2021April). , [https://jbi-global-](https://jbi-global-wiki.refined.site/space/MANUAL/4685874/Downloadable+PDF+-+current+version?attachment=/rest/api/content/4685874/child/attachment/att4691824/download&type=application/pdf&filename=JBIMES_2021April)  
335 [wiki.refined.site/space/MANUAL/4685874/Downloadable+PDF+-](https://jbi-global-wiki.refined.site/space/MANUAL/4685874/Downloadable+PDF+-+current+version?attachment=/rest/api/content/4685874/child/attachment/att4691824/download&type=application/pdf&filename=JBIMES_2021April)  
336 [+current+version?attachment=/rest/api/content/4685874/child/attachment/att4691824](https://jbi-global-wiki.refined.site/space/MANUAL/4685874/Downloadable+PDF+-+current+version?attachment=/rest/api/content/4685874/child/attachment/att4691824/download&type=application/pdf&filename=JBIMES_2021April)  
337 [/download&type=application/pdf&filename=JBIMES\\_2021April](https://jbi-global-wiki.refined.site/space/MANUAL/4685874/Downloadable+PDF+-+current+version?attachment=/rest/api/content/4685874/child/attachment/att4691824/download&type=application/pdf&filename=JBIMES_2021April).

338 ECHA. (2011) Guidance on information requirements and chemical safety assessment. Part  
339 B: Hazard assessment. Version 2.1, The European Chemicals Agency,  
340 [https://echa.europa.eu/documents/10162/17235/information\\_requirements\\_part\\_b\\_e](https://echa.europa.eu/documents/10162/17235/information_requirements_part_b_en.pdf/7e6bf845-e1a3-4518-8705-c64b17cecae8)  
341 [n.pdf/7e6bf845-e1a3-4518-8705-c64b17cecae8](https://echa.europa.eu/documents/10162/17235/information_requirements_part_b_en.pdf/7e6bf845-e1a3-4518-8705-c64b17cecae8).

342 EFSA. (2010) Application of systematic review methodology to food and feed safety  
343 assessments to support decision making. *EFSA Journal* 8:1637. DOI:  
344 <https://doi.org/10.2903/j.efsa.2010.1637>.

345 EFSA, Hardy A., Benford D., Halldorsson T., Jeger M.J., Knutsen H.K., More S., Naegeli H.,  
346 Noteborn H., Ockleford C., Ricci A., Rycken G., Schlatter J.R., Silano V., Solecki R.,



347 Turck D., Benfenati E., Chaudhry Q.M., Craig P., Frampton G., Greiner M., Hart A.,  
348 Hogstrand C., Lambre C., Luttik R., Makowski D., Siani A., Wahlstroem H., Aguilera  
349 J., Dorne J.-L., Fernandez Dumont A., Hempen M., Valtueña M., Martino L., Smeraldi  
350 C., Terron A., Georgiadis N., Younes M. (2017a) Guidance on the use of the weight  
351 of evidence approach in scientific assessments. EFSA Journal 15:e04971. DOI:  
352 10.2903/j.efsa.2017.4971.

353 EFSA, Hardy A., Benford D., Halldorsson T., Jeger M.J., Knutsen H.K., More S., Naegeli H.,  
354 Noteborn H., Ockleford C., Ricci A., Rychen G., Schlatter J.R., Silano V., Solecki R.,  
355 Turck D., Younes M., Bresson J.-L., Griffin J., Benekou S.H., van Loveren H., Luttik  
356 R., Messean A., Penninks A., Ru G., Stegeman J.A., van der Werf W., Westendorf  
357 J., Woutersen R.A., Barizzone F., Bottex B., Lanzoni A., Georgiadis N., Alexander J.  
358 (2017b) Guidance on the assessment of the biological relevance of data in scientific  
359 assessments. EFSA Journal 15:e04970. DOI: 10.2903/j.efsa.2017.4970.

360 EPA. (2022) ORD Staff Handbook for Developing IRIS Assessments. U.S. EPA Office of  
361 Research and Development, Washington, DC, EPA/600/R-22/268,  
362 [https://ordspub.epa.gov/ords/eims/eimscomm.getfile?p\\_download\\_id=545991](https://ordspub.epa.gov/ords/eims/eimscomm.getfile?p_download_id=545991).

363 EPA. (2023) Draft Protocol for Systematic Review in TSCA Risk Evaluations (assessed  
364 10.02.2023), United States Environmental Protection Agency,  
365 [https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/draft-protocol-](https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/draft-protocol-systematic-review-tsca-risk-evaluations)  
366 [systematic-review-tsca-risk-evaluations](https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/draft-protocol-systematic-review-tsca-risk-evaluations).

367 Higgins J., Lasserso T., Thomas J., Flemyng E., Churchill R. (2023) Standards for the  
368 conduct of new Cochrane Intervention Reviews, and the planning and conduct of  
369 updates. Methodological Expectations of Cochrane Intervention Reviews (MECIR).  
370 MECIR Manual (Version August 2023) Cochrane Community,  
371 [https://community.cochrane.org/book\\_pdf/545](https://community.cochrane.org/book_pdf/545).

372 Higgins J., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A., (Editors).  
373 (2022) Cochrane Handbook for Systematic Reviews of Interventions version 6.3  
374 (updated February 2022). Cochrane, 2022. Available from  
375 <https://training.cochrane.org/handbook/current>.

376 Hoffmann S., de Vries R.B.M., Stephens M.L., Beck N.B., Dirven H.A.A.M., Fowle J.R.,  
377 Goodman J.E., Hartung T., Kimber I., Lalu M.M., Thayer K., Whaley P., Wikoff D.,  
378 Tsaion K. (2017) A primer on systematic reviews in toxicology. Archives of  
379 Toxicology 91:2551-2575. DOI: 10.1007/s00204-017-1980-3.

380 Institute of Medicine Committee on Standards for Systematic Reviews of Comparative  
381 Effectiveness R. (2011), in: J. Eden, et al. (Eds.), Finding What Works in Health  
382 Care: Standards for Systematic Reviews, National Academies Press (US) Copyright  
383 2011 by the National Academy of Sciences. All rights reserved., Washington (DC).

384 National Research Council. (2009) Science and Decisions: Advancing Risk Assessment.  
385 Washington, DC: The National Academies Press. <https://doi.org/10.17226/12209>.

386 National Research Council Committee on the Institutional Means for Assessment of Risks to  
387 Public H. (1983), Risk Assessment in the Federal Government: Managing the  
388 Process, National Academies Press (US)

389 Copyright © National Academy of Sciences., Washington (DC).

390 Nettleton D. (2014) Chapter 11 - Text Analysis, in: D. Nettleton (Ed.), Commercial Data  
391 Mining, Morgan Kaufmann, Boston. pp. 171-179.

392 NTP OHAT. (2015) OHAT Risk of Bias Rating Tool for Human and Animal Studies, Office of  
393 Health Assessment and Translation (OHAT), Division of the National Toxicology  
394 Program, National Institute of Environmental Health Sciences,  
395 [https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool\\_508.pdf](https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool_508.pdf).

396 NTP OHAT. (2019) Handbook for Conducting a Literature Based Health Assessment Using  
397 OHAT Approach for Systematic Review and Evidence Integration, Office of Health  
398 Assessment and Translation (OHAT), Division of the National Toxicology Program,  
399 National Institute of Environmental Health Sciences,  
400 [https://ntp.niehs.nih.gov/ntp/ohat/pubs/handbookmarch2019\\_508.pdf](https://ntp.niehs.nih.gov/ntp/ohat/pubs/handbookmarch2019_508.pdf).

401 OECD. (2019) Guiding Principles and Key Elements for Establishing a Weight of Evidence  
402 for Chemical Assessment, Series on Testing and Assessment No. 311, Environment,  
403 Health and Safety Division, Environment Directorate, The Organisation for Economic  
404 Co-operation and Development, [https://www.oecd.org/chemicalsafety/risk-  
405 assessment/guiding-principles-and-key-elements-for-establishing-a-weight-of-  
406 evidence-for-chemical-assessment.pdf](https://www.oecd.org/chemicalsafety/risk-assessment/guiding-principles-and-key-elements-for-establishing-a-weight-of-evidence-for-chemical-assessment.pdf).

407 Sketch Engine. (2023) enTenTen: Corpus of the English Web,  
408 <https://www.sketchengine.eu/ententen-english-corpus/>.

409 Tao T., Bhuller Y., Bonvalot Y., Hill M., Klein A., Kozak G., Plante I., Robert N. (2018)  
410 Weight of Evidence : General Principles and Current Applications at Health Canada.  
411 Prepared for: Task Force on Scientific Risk Assessment; Prepared by: Weight of  
412 Evidence Working Group. ISBN: 978-0-660-27301-3, Health Canada,  
413 [https://www.canada.ca/content/dam/hc-sc/documents/services/publications/science-  
414 research-data/weight-evidence-general-principles-current-applications/weight-  
415 evidence-general-principles-current-applications.pdf](https://www.canada.ca/content/dam/hc-sc/documents/services/publications/science-research-data/weight-evidence-general-principles-current-applications/weight-evidence-general-principles-current-applications.pdf).

416 VKM. (2023) The Norwegian Scientific Committee of Food and Environment (VKM)  
417 participates in the European Partnership for the Assessment of Risks from Chemicals  
418 (PARC) (assessed 11.05.2023),

419 [https://vkm.no/english/parc/parceuropeanpartnershipfortheassessmentofrisksfromche](https://vkm.no/english/parc/parceuropeanpartnershipfortheassessmentofrisksfromchemicals.4.7205492a1864a8c8da2dcfd9.html)  
420 [micals.4.7205492a1864a8c8da2dcfd9.html](https://vkm.no/english/parc/parceuropeanpartnershipfortheassessmentofrisksfromchemicals.4.7205492a1864a8c8da2dcfd9.html).

421 Whaley P., Halsall C., Ågerstrand M., Aiassa E., Benford D., Bilotta G., Coggon D., Collins  
422 C., Dempsey C., Duarte-Davidson R., FitzGerald R., Galay-Burgos M., Gee D.,  
423 Hoffmann S., Lam J., Lasserson T., Levy L., Lipworth S., Ross S.M., Martin O.,  
424 Meads C., Meyer-Baron M., Miller J., Pease C., Rooney A., Sapiets A., Stewart G.,  
425 Taylor D. (2016) Implementing systematic review techniques in chemical risk  
426 assessment: Challenges, opportunities and recommendations. *Environ Int* 92-  
427 93:556-64. DOI: 10.1016/j.envint.2015.11.002.

428 WHO. (2021) Framework for the use of systematic review in chemical risk assessment.  
429 Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO,  
430 <https://apps.who.int/iris/rest/bitstreams/1387316/retrieve>.

431 Woodruff T.J., Sutton P. (2014) The Navigation Guide systematic review methodology: a  
432 rigorous and transparent method for translating environmental health science into  
433 better health outcomes. *Environ Health Perspect* 122:1007-14. DOI:  
434 10.1289/ehp.1307175.

435